Scott Biller

Scott Biller is currently Director at OMass Therapeutics Ltd. since 2022, Independent Director at Foghorn Therapeutics, Inc. since 2020, Director at Remix Therapeutics, Inc. since 2020, and Director at Rome Therapeutics, Inc. since 2021.
Formerly, Dr. Biller was Chief Scientific Officer at Agios Pharmaceuticals, Inc. from 2010 to 2019, Vice President & Head-Global Discovery Chemistry at Novartis Institutes for Biomedical Research, Inc. from 2003 to 2010, and VP-Pharmaceutical Candidate Optimization at Bristol-Myers Squibb Pharmaceutical Research Institute from 2001 to 2003.
Education includes an undergraduate degree from Massachusetts Institute of Technology in 1976 and a doctorate from California Institute of Technology in 1981.